Alleyba, good to see you posting again. $60M+ ann

Alleyba, good to see you posting again. $60M+ annual run rate and profitable are two characteristics of a company moving forward. I agree the SeeThruEquity is conservative. Also, I feel with the imminent launch of RapiMeds, and the expansion into other States with compounding, the $60M+ 2015 annual run rate projection is also very conversation. This company is on the verge of greatness and I do believe will be one of the biggest success stories for 2015. The current pps of .115 is an incredible buying opportunity for any investor looking for long term profitability.